title: Effect of low dose mineralocorticoid receptor antagonist eplerenone on glucose and lipid metabolism in healthy adult males.
abstract: Mineralocorticoid Receptor (MR) activation is involved in blood pressure regulation and the pathogenesis of cardiovascular diseases, such as cardiac fibrosis, vascular inflammation and arterial aging. Recent investigations suggest a role for MR activation in metabolic dysregulation.
  
  
  OBJECTIVE
  To test the effect of MR blockade on basal and postprandial glucose and lipid levels after a meal high in fat and glucose in healthy males.
  
  
  METHODS
  A prospective, self-controlled study was performed in 13 healthy adult males aged 18-45years. Blood was drawn before, 2h, and 4h after a high fat/high glucose meal (50g fat, 75g glucose), followed by low-dose eplerenone treatment (50mg daily) for 14days. Subjects returned for a second high fat/high glucose meal after the medication period. Basal and postprandial blood glucose and lipid levels were compared before and after eplerenone treatment.
  
  
  RESULTS
  Eplerenone treatment affected neither basal nor postprandial glucose and lipid levels in our study population.
  
  
  CONCLUSIONS
  Our results suggest that low-dose, non-blood pressure-affecting, MR blockade does not alter postprandial lipid and glucose homeostasis in healthy adult subjects.
authors.affiliation: Brigham and Women's Hospital, Harvard Medical School, Division of Endocrinology, Diabetes, and Hypertension, Boston, USA. alexander.krug@t-online.de
authors.forename: Alexander W
authors.initials: AW
authors.lastname: Krug
authors.forename: Lissy
authors.initials: L
authors.lastname: Stelzner
authors.forename: Ajaykumar D
authors.initials: AD
authors.lastname: Rao
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Lichtman
authors.forename: Gordon H
authors.initials: GH
authors.lastname: Williams
authors.forename: Gail K
authors.initials: GK
authors.lastname: Adler
mesh_terms: D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D000077545:Eplerenone; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology*; D019518:Postprandial Period / Q000187:drug effects; D011446:Prospective Studies; D018161:Receptors, Mineralocorticoid / Q000378:metabolism*; D012044:Regression Analysis; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000494:pharmacology; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D007328:Insulin; D000451:Mineralocorticoid Receptor Antagonists; D018161:Receptors, Mineralocorticoid; D013148:Spironolactone; D000077545:Eplerenone; D002784:Cholesterol; D005947:Glucose